Lista de obras -

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

artículo científico publicado en 2013

Antiretroviral drug treatment of CNS HIV-1 infection ⬇️

artículo científico publicado el 8 de diciembre de 2011

Antiretroviral treatment for HIV infection: Swedish recommendations 2019

scientific article published on 11 January 2020

Antiretroviral treatment of central nervous system HIV‐1 infection: a review ⬇️

artículo científico publicado el 1 de abril de 2001

Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations

artículo científico publicado en 2003

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection

artículo científico publicado en 2013

Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy

artículo científico publicado en 2011

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

artículo científico publicado en 2011

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection

artículo científico publicado en 2014

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections ⬇️

artículo científico publicado el 9 de octubre de 2012

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load ⬇️

artículo científico publicado el 10 de septiembre de 2012

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients

artículo científico publicado en 2016

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy ⬇️

artículo científico publicado el 10 de mayo de 2013

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

artículo científico publicado en 2010

Cognitive and neuronal link with inflammation: a longitudinal study in people with and without HIV infection

scientific article published on 11 September 2020

Contagiousness in treated HIV-1 infection

artículo científico publicado en 2020

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers

scientific article published on 12 September 2006

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

artículo científico publicado en 2019

Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption

artículo científico publicado en 2020

HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir

artículo científico publicado el 1 de enero de 1998

HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy ⬇️

artículo científico publicado el 15 de julio de 1997

HIV-1 infection and cognitive impairment in the cART era: a review ⬇️

artículo científico publicado el 13 de marzo de 2011

HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries

artículo científico publicado en 2016

Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance

artículo científico publicado en 2020

Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels

artículo científico publicado el 1 de diciembre de 2001

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy

artículo científico publicado en 2013

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial

artículo científico publicado en 2013

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation

artículo científico publicado en 2014

Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010

artículo científico publicado en 2012

Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review ⬇️

artículo científico publicado el 19 de septiembre de 2011

Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden ⬇️

artículo científico publicado el 1 de enero de 2010

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

artículo científico publicado en 2020

No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach

artículo científico publicado en 2021

Non-AIDS Mortality Is Higher Among Successfully Treated People Living with HIV Compared with Matched HIV-Negative Control Persons: A 15-Year Follow-Up Cohort Study in Sweden

article

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients ⬇️

artículo científico publicado el 2 de octubre de 2011

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate

artículo científico publicado en 2019

Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence

scientific article published on 01 December 2019

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection

artículo científico publicado en 2014

Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden

artículo científico publicado en 2017

Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy

artículo científico publicado en 2014

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

scientific article published on 21 October 2020

Surveillance of wastewater revealed peaks of SARS-CoV-2 preceding those of hospitalized patients with COVID-19

artículo científico publicado en 2020

Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection

artículo científico publicado en 2019

Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades

artículo científico publicado en 2014

Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels

artículo científico publicado en 2016

Lista de obras de

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

Antiretroviral drug treatment of CNS HIV-1 infection ⬇️

Antiretroviral treatment for HIV infection: Swedish recommendations 2019

Antiretroviral treatment of central nervous system HIV‐1 infection: a review ⬇️

Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection

Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections ⬇️

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load ⬇️

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy ⬇️

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

Cognitive and neuronal link with inflammation: a longitudinal study in people with and without HIV infection

Contagiousness in treated HIV-1 infection

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption

HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir

HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy ⬇️

HIV-1 infection and cognitive impairment in the cART era: a review ⬇️

HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries

Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance

Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation

Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010

Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review ⬇️

Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden ⬇️

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach

Non-AIDS Mortality Is Higher Among Successfully Treated People Living with HIV Compared with Matched HIV-Negative Control Persons: A 15-Year Follow-Up Cohort Study in Sweden

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients ⬇️

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate

Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection

Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden

Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

Surveillance of wastewater revealed peaks of SARS-CoV-2 preceding those of hospitalized patients with COVID-19

Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection

Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades

Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels